MoneyWorks4Me

Biocon divests 5.4% stake in Syngene International

07 Sep 2022 Evaluate

Biocon has divested 5.4 per cent stake in its research arm -- Syngene International -- for a little over Rs 1,220 crore through an open market transaction. According to bulk deal data available with the BSE, the company has sold a total of 21,789,164 shares, at an average price of Rs 560.04 apiece, in Syngene International.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Peers
Company Name CMP
Sun Pharma. Inds. 1782.00
Dr. Reddys Labs. 1208.00
Cipla 1334.00
Lupin 2010.00
Zydus Lifesciences 1138.50
View more..